Involvement of fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia

Blood

Volumn 89, Issue 3, 1997, Pages 957-964

  Selleri, Carmine ^b   Sato, Tadatsugu ^b   Del Vecchio, Luigi ^b   Luciano, Luigia ^b   Barrett, A John ^b   Rotoli, Bruno ^b   Young, Neal S ^b   Maciejewski, Jaroslaw P ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; FAS ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; ETIOLOGY; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

EID: 0030969311     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.957     Document Type: Article

References (60)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63:125, 1972
2. Martin PJ, Najfield V, Hansen JA, Penfold JK, Fialkow PJ: Involvement of the B-lymphoid system in chronic myelogenous leukemia. Nature 287:49, 1980
3. Nitta M, Kato Y, Strife A, Wachter M, Fried J, Perez A, Jhanwar S, Duigou-Ostendorf R, Chaganti RSK, Clarkson B: Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 66:1053, 1985
4. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290, 1973
5. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
6. Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990, 1988
7. Heisterkamp N, Jenster G, ten-Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukemia in bcr/abl transgenic mice. Nature 344:251, 1990
8. McWhirter JR, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/ abl fusion protein. Mol Cell Biol 11:1553, 1991
9. Cotter TG: bcr-abl: An anti-apoptosis gene in chronic myelogenous leukemia. Leuk Lymphoma 18:231, 1995
10. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood 83:2038, 1994
11. Bedi A, Barber JP, Bedi GC, El-Deiry S, Sidranski D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: bcr-abl-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
12. McGahon A, Bissonette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
13. Amos TAS, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY: Apoptosis in chronic myeloid leukemia: Normal responses by progenitor cells to growth factor deprivation, x-irradiation and glucocorticoids. Br J Haematol 91:387, 1995
14. Gordon MY, Dowding CR, Riley GP, Goldman JM: Altered adhesive interactions with marrow stroma of haematopoietic cells in chronic myeloid leukemia. Nature 328:342, 1987
15. Verfaillie CM, McCarthy JB, McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J Clin Invest 90:1232, 1992
16. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M: Alteration in bone marrow adherent layer growth factor expression: A novel mechanism of chronic myelogenous leukemia progression. Blood 78:2400, 1991
17. Bathia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM: Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages. Blood 85:3636, 1995
18. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic phase myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
19. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 30:820, 1994
20. Talpaz M, Kantarijian H, Kurzrock R, Trujillo JM, Guttermann JU: Interferon-alpha produces sustained cytogenetic response in chronic myeloid leukemia. Ann Intern Med 114:532, 1991
21. Lee MS, Kantarijian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA: Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79:1920, 1992
22. Broxmeyer HE, Lu E, Platzer E, Feit C, Juliano L, Rubin BY: Comparative analyses of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte macrophage (CFU-GM) progenitor cells. J Immunol 131:1330, 1983
23. Geissler D, Gastl G, Aulitzky W, Tilg H, Gaggl S, Konwalinka G, Huber C: Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: Relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response. Leuk Res 14:629, 1990
24. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG: Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88:2131, 1991
25. Dowding C, Guo AP, Osterholz J, Sickowski M, Goldman J, Gordon M: Interferon-alpha overrides the deficient adhesion of chronic myelogenous leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78:499, 1991
26. Bathia R, McGlave P, Verfaillie CM: Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1α. J Clin Invest 96:931, 1995
27. Aman JM, Keller U, Derigs G, Mohammadzadeh M, Huber C, Peschel C: Regulation of cytokine expression by interpheron alpha in human bone marrow stroma cells: Inhibition of hematopoietic growth factors and induction of IL-1 receptor antagonist. Blood 84:4142, 1994
28. Bathia R, McGlave PB, Verfaillie CM: Interpheron-α treatment of marrow stroma results in enhanced adhesion of chronic myelogenous leukemia progenitors via mechanism involving MIP-1α and TGF-β. Exp Hematol 22:797a, 1994 (abstr)
29. Dowding C, Guo AP, Maisin D, Gordon MY, Goldman JM: The effects of the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br J Haematol 77:165, 1991
30. Zoumbos N, Gascon P, Young NS: The induction of lymphocytes in normal and suppressed hematopoiesis. Blut 48:1, 1984
31. Emerson SB, Antin JH: Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response. J Immunol 142:766, 1989
32. Cashmann JD, Eaves AC, Raines EW, Ross R, Eaves CJ: Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cell within the adherent layer. Blood 78:110, 1991
33. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP: Interferon-γ and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 165:538, 1995
34. + human bone marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokinemediated hematopoietic suppression in vitro. Blood 85:3183, 1995
35. + cells. Blood 36:443a, 1995 (abstr, suppl 1)
36. Sato T, Selleri C, Young NS, Maciejewski J: Hematopoietic inhibition by interferon-γ is partially mediated through interferon regulatory factor-1. Blood 86:3373, 1995
37. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo T, Niho Y: Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 86:883, 1995
38. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide sequence encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
39. Oehm A, Behrman I, Falk W, Pawlita M: Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267:10709, 1992
40. Kagi D, Vignaux F, Ledermenn B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perform pathways as major mechanisms of T-cell mediated cytotoxicity. Science 265:528, 1994
41. 2+-independent T cell-mediated cytotoxicity. J Exp Med 177:195, 1993
42. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara Y, Yagita H, Okumura K: Fas and its ligand is a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
43. Owen-Schaub LB, Meterissian S, Ford RJ: Fas/APO-1 expression and function on malignant cells of hematologic and non-hematologic origin. J Immunother 14:234, 1993
44. Debatin KM, Goldmann CK, Waldmann TA, Krammer PH: APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 81:2972, 1993
45. Mapara MY, Bargou R, Zugks C, Dohner H, Ustaoglu F, Jonker RR, Krammer PH, Dorkenn B: Apo-1 mediates apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression. Eur J Immunol 23:702, 1993
46. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J: Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17:51, 1994
47. Munker R, Lubbert M, Yonehara S, Tuchnitz A, Mertelsmann R, Wilmanns W: Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 70:15, 1995
48. Westendorf JJ, Lammert JM, Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85:3566, 1995
49. Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, Bianchi A, Boccadoro M, Pileri A: Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85:3679, 1995
50. Takizawa T, Matsukawa S, Higuchi Y, Nakamura S, Nakanishi Y, Fukuda R: Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J Gen Virol 74:2347, 1993
51. Gissingler H, Kurzrock K, Jang S, Andreeff M, Talpaz M: FAS/APO1, another interferon inducible gene. Blood 86:541a, 1995 (abstr, suppl 1)
52. Gutterman JU, Fine S, Quesada J, Hornong SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanoski Z: Recombinant leucocyte α interferon: Pharmacokinetics, single-dose tolerance, and biological effects in cancer patients. Ann Intern Med 96:549, 1982
53. Champlin R: Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 23:1148, 1995
54. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implication for graft-ver-sus-leukemia reactivity. Blood 86:2821, 1995
55. Jiang Y-Z, Barrett J: Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 23:1167, 1995
56. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T: Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354, 1994
57. Fisher T, Aman J, van der Kuip H, Peschel C, Aulitzky WE, Huber C: Induction of interferon regulatory factors, 2′-5′ oligoadenylate synthetase, P68 kinase and Rnase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness. Br J Haematol 92:595, 1996
58. Cheng J, Liu C, Koopman WJ, Mountz JD: Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 154:1239, 1995
59. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811, 1996
60. Roger R, Isaad C, Pallardy M, Leglise M-C, Turhan AG, Bertoglio J, Breard J: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 87:1113, 1996